Kiora Pharmaceuticals
KPRX | NASDAQ
$0.98
-$0.25 (-20.33%)
At close: Nov 16, 2026, 4:00 PM ET
$1.00
+$0.02 (+2.04%)
After-hours:
Nov 16, 2026, 7:05 PM ET
Kiora Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Key Executives
| Name | Position |
|---|---|
| Brian Strem | President, Chief Executive Officer & Director |
| Melissa Tosca | Chief Financial Officer |
| Keith J. Lane | Executive VP and Head of Clinical Development & Regulatory Affairs |
| Stefan Sperl | Executive Vice President of CMC & Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 8-K | Current Report |
| Sep 17, 2026 | 4 | Filing |
| Sep 17, 2026 | 3 | Filing |
| Sep 17, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 08, 2026 | 8-K | Current Report |
| Aug 19, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 10, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 07, 2026 | 8-K | Current Report |
Kiora Pharmaceuticals
| Country | United States |
| IPO Date | Feb 13, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Brian Strem |
Contact Details
332 Encinitas Boulevard Encinitas,
California 92024 United States
Stock Details
| Ticker Symbol | KPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001372514 |
| CUSIP Number | 49721T507 |
| ISIN Number | US49721T5074 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove KPRX